a Interventional Radiology, Beijing Friendship Hospital , Capital Medical University , Beijing , China.
b The Department of Immunology, School of Basic Medical Sciences , Capital Medical University , Beijing , China.
Cancer Biol Ther. 2019;20(2):212-218. doi: 10.1080/15384047.2018.1523847. Epub 2018 Oct 8.
Bone metastases are the most common sites for malignant tumors. Patients who failed to respond to initial first-line treatment with bisphosphonates usually suffer from extreme pain. The aim of this study was to observe the efficacy of arterial chemoembolization combined with Iodine-125 seed implantation in the treatment of bone metastatic cancer pain. All 14 patients with metastatic bone tumor wo failed first-line treatment underwent arterial chemoembolization the day before the implantation of the particles. A computer stereoscopic TPS was used to design the treatment plans, the number and dose of particles required for implantation. Pain relief was evaluated using several parameters such as Visual Analog Scale (VAS) and Verbal Rating Scales (VRS). Pain intensity was measured pre-operation and 1-week, 1-month, 3-month after the treatment. Meanwhile, we also assessed tumor size using computer tomography (CT). Pain palliation was observed in 35.7% (5/14), 57.1% (8/14), and 78.6% (11/14) of all patients at 1-week, 1-month and 3-month post treatment. Likewise, our analysis showed that the combination therapy resulted in a significant decrease of VAS score (6.71 ± 0.49 before treatment vs 3.36 ± 0.40 at 3 month post treatment) and overall responding rate of 92.0% using VRS pain assessment. Consistently, tumor size was reduced from 42.16 ± 10.32 before treatment to 29.11 ± 8.73 at 3 months post treatment. No serious complications were detected. Our study demonstrate that the combination of arterial chemoembolization and I particles resulted in evident pain relief and reduction of tumor burden, suggesting that the combination treatment could be a feasible and promising therapy for bone tumor management.
骨转移是恶性肿瘤最常见的转移部位。那些对最初一线双膦酸盐治疗无反应的患者通常会遭受极度疼痛。本研究旨在观察动脉化疗栓塞联合碘-125 粒子植入治疗骨转移性癌痛的疗效。所有 14 例一线治疗失败的转移性骨肿瘤患者在粒子植入前一天进行动脉化疗栓塞。采用计算机立体 TPS 设计治疗方案,需要植入的粒子数量和剂量。使用视觉模拟量表(VAS)和语言评定量表(VRS)等多个参数评估疼痛缓解情况。在治疗前、治疗后 1 周、1 个月和 3 个月测量疼痛强度。同时,我们还使用计算机断层扫描(CT)评估肿瘤大小。治疗后 1 周、1 个月和 3 个月,所有患者中分别有 35.7%(5/14)、57.1%(8/14)和 78.6%(11/14)观察到疼痛缓解。同样,我们的分析表明,联合治疗可显著降低 VAS 评分(治疗前为 6.71±0.49,治疗后 3 个月为 3.36±0.40)和 VRS 疼痛评估的总反应率为 92.0%。一致地,肿瘤大小从治疗前的 42.16±10.32 减小到治疗后 3 个月的 29.11±8.73。未发现严重并发症。我们的研究表明,动脉化疗栓塞联合碘粒子治疗可明显缓解疼痛和减轻肿瘤负担,表明联合治疗可能是骨肿瘤管理的一种可行且有前途的治疗方法。